Abbisko Therapeautics
Executivos
Veja o organograma con seus 6 executivos principais
Biografias mais buscadas da Abbisko Therapeautics
- Jia Feng, Head of Human Resource
- Jing Ji, Chief Medical Officer
- Zidong Zhang, Chief Financial Officer
Criar um alerta
para seguir os movimentos de executivos da Abbisko Therapeautics.
Biotecnologia
Abbisko Therapeautics possui 2.284 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado em 2 de maio de 2024).
- Enlaza Therapeutics acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Abbisko Therapeautics
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib（ABSK021）
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 ESMO TAT Oral Presentation — Abbisko Therapeutics presented preliminary first-in-human trial results of its selective FGFR2/3 inhibitor ABSK061
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics will present 3 pre-clinical research results with oral presentation and posters
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Merck Delegation Visited Abbisko Shanghai R&D Center
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutic Completed the First Patient Dose in Phase I Clinical Trial for Novel Small Molecule CD73 Inhibitor ABSK051
- View more press releases Close
Redes sociais sobre Abbisko Therapeautics
- Abbisko Therapeautics na Wikipedia, Google News e Yahoo Finance
- Abbisko Therapeautics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Zidong Zhang 
Ligue para a Abbisko Therapeautics em +86 ...
